Tegoprazan, a novel and potent P-CAB (potassium-competitive acid blocker), is a next-generation therapeutics developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and peptic ulcers, acting by controling gastric acid secretion and motility.